Cash and cash equivalents as of March 31, 2025 were approximately $16.4 million and total obligated grant funds remaining from the National Institute of Aging, a division of the National Institute of Health were $47.0 million. The Company estimates that it has sufficient cash to fund operations and capital expenditures into the fourth quarter of 2025.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGTX:
- Cognition Therapeutics presents results at AD/PD 2025 on CT1812
- Buy Recommendation for Cognition Therapeutics: Promising Phase 2 Results and Strategic Focus on Alzheimer’s and Dementia Indications
- Cognition Therapeutics price target lowered to $5 from $6 at H.C. Wainwright
- Cognition Therapeutics Earnings Call: Progress Amid Challenges
- Cognition Therapeutics price target lowered to $8 from $11 at Chardan